Clinical Trial Update: Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Update on safety results from a combination therapy using an adenovirus vector engineered to express hIL-12 with an Activator Ligand in melanoma (Phase 1/Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Activator Ligand (activator ligand)
• Adenovirus vector expressing human interleukin-12 (hIL-12) (adenoviral vector encoding interleukin-12)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-29